Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026
Cells · 20.03.2026 · 15 (6) · 561
DOI: 10.3390/cells15060561 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 20.03.2026. Verfasst von James Poe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, School of Medicine, Stanford University, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: Glioblastoma, Immunotherapy, Brain Neoplasms, Precision Medicine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 247 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM) persists as one of the greatest challenges in the treatment of human cancer, despite extensive efforts to leverage the therapeutic potential of immunotherapy. While checkpoint blockade and other forms of immunotherapy have revolutionized the treatment of various cancers, their therapeutic efficacy in GBM has been hindered by the profound immunosuppressive environment, spatial heterogeneity, and dynamic immune metabolic challenges associated with the tumor microenvironment. In this review, we will synthesize recent advances and insights to develop a next-generation framework for GBM immunotherapy based on systems biology approaches to understanding the complex interplay between GBM and the immune system, as opposed to single-axis approaches to immune activation and modulation. We will discuss how the functional competence of the interferon system, myeloid antigen presentation status, T-cell clone status, spatial organization of the immune microenvironment, and resource competition between GBM and the immune system dictate therapeutic responsiveness. Furthermore, the current paper elucidates how recent advances in spatial transcriptomics, single-cell analysis, and high-parameter imaging enable us to understand how immune phenotype status varies across GBM regions and treatment status, and how this information can be used to develop predictive and pharmacodynamic biomarkers of therapeutic efficacy and failure. We will then discuss how these advances form the basis for rational combination approaches to GBM immunotherapy, which involve the integration of checkpoint blockade with metabolic reprogramming, myeloid modulation, and interferon system reactivation, and how artificial intelligence-based analytics and adaptive clinical trial design can guide the development of biomarker-based therapeutic selection approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, School of Medicine, Stanford University, Stanford, CA 94305, USA.
- Department of Radiation Oncology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
ORCID-Profile: James Poe, Claire Kim, Campbell Coleman, Hieu Nguyen, Brandon Bergsneider, Vivek Sanker, Matthew Abikenari
Zitieren
APA
Poe, J., Kim, C., Coleman, C., Nguyen, H., Velazhahan, V., Bergsneider, B., Sanker, V., Kim, S., Chen, Y., Abikenari, M., Choi, J., & Lim, M. (2026). Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026. Cells, 15(6), 561. https://doi.org/10.3390/cells15060561
Vancouver
Poe J, Kim C, Coleman C, Nguyen H, Velazhahan V, Bergsneider B, et al. Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026. Cells. 2026;15(6):561. doi:10.3390/cells15060561
BibTeX
@article{Poe2026,
author = {Poe, James and Kim, Claire and Coleman, Campbell and Nguyen, Hieu and Velazhahan, Vaithish and Bergsneider, Brandon and Sanker, Vivek and Kim, Samuel and Chen, Yijiang and Abikenari, Matthew and Choi, John and Lim, Michael},
title = {Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026},
journal = {Cells},
year = {2026},
volume = {15},
number = {6},
pages = {561},
doi = {10.3390/cells15060561}
}
EUVIMED